Income StatementBalance SheetCash FlowSegments
Pfizer logo

Pfizer Cash Flow Statement

Operating, investing, and financing cash movements

Pfizer generated $12.0B in operating cash flow over the trailing twelve months. After $2.5B in capital expenditures, free cash flow was $9.5B. Free cash flow decreased 0.2% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$12.0BNet Cash From Investing (TTM)-$3.8BNet Cash From Financing (TTM)-$8.5BCapital Expenditures (TTM)$2.5BDepreciation And Amortization Cf (TTM)$6.6BNet Change In Cash (TTM)$242.0M
Latest FilingQ1 2026
Report Date2026-05-05
Market Cap$144.37B
P/E Ratio11.93
ROE13.4%

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Capital expenditures$917.0M$564.0M$618.0M$602.0M$845.0M$436.0M
Payment for (Proceeds from) Other Investing Activity—-$300.0M———-$22.0M
Payments to Acquire Short-Term Investments—$2.8B———$2.6B
Proceeds from maturities of short-term investments—$4.0B———$4.6B
Proceeds from redemptions/sales of long-term investments—$82.0M———$88.0M
Sales of and distributions from equity method investments—$6.3B———$0.0
Net cash from investing activities—$3.3B$4.0B-$2.4B-$6.1B$785.0M
Net Change in Short-Term Investments (Under 3 Months)-$487.0M$3.9B-$1.2B$583.0M—$792.0M

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Change in accounts payable-$255.8M-$117.3M-$117.3M-$117.3M-$117.3M—
Change in accounts receivable$27.3M$65.8M$65.8M$65.8M$65.8M—
Change in income taxes payable/receivable-$336.3M-$701.3M-$701.3M-$701.3M-$701.3M—
Change in inventories$213.5M-$140.3M-$140.3M-$140.3M-$140.3M—
Change in other assets-$845.0M-$322.3M-$322.3M-$322.3M-$322.3M—
Change in other liabilities-$778.8M-$916.8M-$916.8M-$916.8M-$916.8M—
Deferred income taxes-$396.0M-$663.0M-$272.0M-$765.0M-$433.0M-$12.0M
Depreciation and amortization$1.8B$1.6B$1.6B$1.7B$1.7B$1.6B
Net cash from operating activities$6.7B$2.3B-$582.0M$4.6B$5.3B$2.6B
Net income$418.0M$3.0B$2.9B$3.6B—$2.7B
Net income from discontinued operations—$0.0———-$13.0M
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital—$1.9B———$1.7B
Other Noncash Income (Expense)—-$40.0M———$93.0M
Pension and Postretirement Contributions Net of Expense—$229.0M$105.0M$84.0M$368.0M$173.0M
Write-offs—$344.0M———$32.0M
Stock-based compensation$177.0M$170.0M$203.0M$201.0M$225.0M$272.0M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Payments of Ordinary Dividends—$2.4B———$2.4B
Other, net—-$356.0M———-$284.0M
Short-term borrowings/(repayments) less than 90 days — net—-$386.0M———-$127.0M
Repayments of Short-Term Debt—$2.0B———$0.0
Net cash from financing activities-$5.1B-$5.2B-$3.2B-$2.5B$0.0-$2.9B

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$5.8B$1.8B-$1.2B$4.0B$4.5B$2.2B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$29.0M-$7.0M$41.0M$2.0M$5.0M$19.0M
Net increase (decrease) in cash-$45.0M$375.0M$213.0M-$301.0M—$563.0M

Supplemental

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Interest paid$1.4B$353.0M$1.1B$275.0M$981.0M$293.0M
Interest Rate Hedges$147.0M$74.0M-$45.0M$66.0M$45.0M$62.0M
Income Taxes Paid, Net—$152.0M———$72.0M